Trial Profile
A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin Paclitaxel Plus Concurrent and Extended Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated, Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 26 Jun 2023 Status changed from active, no longer recruiting to completed.
- 02 Sep 2021 Planned End Date changed from 30 Jun 2023 to 1 Jul 2023.
- 16 Jul 2020 Planned End Date changed from 6 May 2021 to 30 Jun 2023.